WeVote
Log In

Bill

Bill

H 137

UNIFORM CONTROLLED SUBSTANCES – Amends existing law to classify mifepristone and misoprostol as schedule IV drugs.

68th Legislature, 1st Regular Session (2025)

House Bill 137 classifies mifepristone and misoprostol as Schedule IV drugs, tightening regulations for healthcare providers and potentially affecting patient access.

Reported Printed and Referred to Health & Welfare
#controlledsubstances #health #healthcareprofessionsandproviders #medical
0
WeVote Research Nonpartisan
Bill Summary · H 137

Summary of House Bill 137 (H 137)

Bill Overview

  • Bill Number: H 137
  • Title: Uniform Controlled Substances – Amends existing law to classify mifepristone and misoprostol as Schedule IV drugs.
  • Status: Reported Printed and Referred to Health & Welfare
  • Introduced: February 04, 2025
  • Classification: Bill
  • Subject: Controlled Substances, Health, Health Care Professions and Providers, Medical

Purpose and Intent

House Bill 137 aims to amend the Idaho Uniform Controlled Substances Act by adding mifepristone and misoprostol to the list of Schedule IV controlled substances. This classification is intended to regulate the use, distribution, and prescription of these medications more strictly.

Key Provisions

  • Amendment to Idaho Code: The bill specifically amends Section 37-2711 of the Idaho Code to include mifepristone and misoprostol in the Schedule IV category.
  • Definition of Schedule IV Drugs: Schedule IV drugs are substances that have a lower potential for abuse relative to Schedule I-III drugs, but still require regulation due to their potential for dependence and misuse.
  • Emergency Clause: The bill includes an emergency declaration, stating that it will take effect on July 1, 2025, allowing for immediate implementation of the new regulations.

Impact

  • Who is Affected:

    • Healthcare Providers: Physicians, pharmacists, and other healthcare professionals will need to adhere to the new regulations regarding the prescription and distribution of mifepristone and misoprostol.
    • Patients: Individuals seeking medical treatment involving these medications may face changes in access and availability due to the new classification.

  • Fiscal Impact: According to the fiscal note attached to the bill, there will be no increase or decrease in revenue or additional expenditures at the state or local government levels as a result of this legislation.

Legislative Timeline

  • February 04, 2025: Bill introduced and read for the first time.
  • February 05, 2025: Bill reported printed and referred to the Health & Welfare Committee for further consideration.

Conclusion

House Bill 137 represents a significant regulatory change concerning mifepristone and misoprostol in Idaho. By classifying these drugs as Schedule IV substances, the bill aims to enhance oversight and control over their use, reflecting ongoing discussions about the management of controlled substances in healthcare.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.